CCM
Cutter Capital Management Portfolio holdings
AUM
$230M
This Quarter Return
-6.02%
1 Year Return
+11.51%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$244M
AUM Growth
+$244M
(-28%)
Cap. Flow
-$79.1M
Cap. Flow
% of AUM
-32.43%
Top 10 Holdings %
Top 10 Hldgs %
68.7%
Holding
38
New
11
Increased
8
Reduced
2
Closed
17
Top Buys
| 1 |
Johnson & Johnson
JNJ
|
$20.5M |
| 2 |
AbbVie
ABBV
|
$18.1M |
| 3 |
Teva Pharmaceuticals
TEVA
|
$12.9M |
| 4 |
Regeneron Pharmaceuticals
REGN
|
$12.1M |
| 5 |
Amgen
AMGN
|
$9.93M |
Top Sells
| 1 |
Gilead Sciences
GILD
|
$30.1M |
| 2 |
Bristol-Myers Squibb
BMY
|
$29.7M |
| 3 |
Agilent Technologies
A
|
$17.9M |
| 4 |
Legend Biotech
LEGN
|
$15.9M |
| 5 |
Eli Lilly
LLY
|
$15.3M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Regeneron Pharmaceuticals
REGN
$61.5B
| $22.4M | 9.19% |
31,500
+17,024
| +118% | +$12.1M |
|
|
2
Johnson & Johnson
JNJ
$427B
| $20.5M | 8.39% |
+141,572
| New | +$20.5M |
|
3
Royalty Pharma
RPRX
$15.6B
| $19.5M | 8% |
764,859
+100,000
| +15% | +$2.55M |
|
|
4
AbbVie
ABBV
$372B
| $18.1M | 7.43% |
+101,996
| New | +$18.1M |
|
5
Ultragenyx Pharmaceutical
RARE
$2.89B
| $17.1M | 7.01% |
406,803
+120,000
| +42% | +$5.05M |
|
6
BridgeBio Pharma
BBIO
$9.89B
| $15.4M | 6.3% |
560,344
+163,956
| +41% | +$4.5M |
|
7
Sarepta Therapeutics
SRPT
$1.78B
| $15.1M | 6.19% |
124,256
+40,500
| +48% | +$4.92M |
|
8
Insmed
INSM
$28.8B
| $14.6M | 5.97% |
210,884
-5,000
| -2% | -$345K |
|
|
9
Teva Pharmaceuticals
TEVA
$21.1B
| $12.9M | 5.28% |
+584,883
| New | +$12.9M |
|
10
Viridian Therapeutics
VRDN
$1.5B
| $12.1M | 4.94% |
628,677
+110,000
| +21% | +$2.11M |
|
|
11
Amgen
AMGN
$155B
| $9.93M | 4.07% |
+38,090
| New | +$9.93M |
|
12
Agios Pharmaceuticals
AGIO
$2.19B
| $9.91M | 4.06% |
301,623
+115,000
| +62% | +$3.78M |
|
13
Vera Therapeutics
VERA
$1.38B
| $8.99M | 3.69% |
212,696
+39,820
| +23% | +$1.68M |
|
14
NewAmsterdam Pharma
NAMS
$2.71B
| $8.66M | 3.55% |
+337,152
| New | +$8.66M |
|
15
Moderna
MRNA
$9.37B
| $8.21M | 3.37% |
+197,500
| New | +$8.21M |
|
16
Perrigo
PRGO
$3.27B
| $7.57M | 3.1% |
294,517
-263,420
| -47% | -$6.77M |
|
17
Janux Therapeutics
JANX
$1.37B
| $6.42M | 2.63% |
+120,000
| New | +$6.42M |
|
18
Akero Therapeutics
AKRO
$3.74B
| $6.4M | 2.62% |
+230,000
| New | +$6.4M |
|
19
Tarsus Pharmaceuticals
TARS
$2.47B
| $6.23M | 2.55% |
+112,500
| New | +$6.23M |
|
|
CNTA
20
Centessa Pharmaceuticals
CNTA
$2.25B
| $2.46M | 1.01% |
+147,076
| New | +$2.46M |
|
21
Neumora Therapeutics
NMRA
$280M
| $1.59M | 0.65% |
+150,000
| New | +$1.59M |
|
|
22
Agilent Technologies
A
$35.7B
| – | – |
-120,485
| Closed | -$17.9M |
|
23
Arcellx
ACLX
$3.85B
| – | – |
-89,863
| Closed | -$7.5M |
|
|
AVDL
24
Avadel Pharmaceuticals
AVDL
$1.43B
| – | – |
-385,172
| Closed | -$5.05M |
|
25
Axsome Therapeutics
AXSM
$6.05B
| – | – |
-105,767
| Closed | -$9.51M |
|